Newsmeme!
Discover News you didn't know existed
Amylin Pharmaceuticals, Inc, Eli Lilly and Company and Alkermes, Inc announced that the New Drug Application (NDA) for exenatide once weekly has been accepted for review by the US Food and Drug Administration (FDA).
Tokyo and Osaka, Japan - July 8, 2009 – Wyeth K.K. (Wyeth) and Takeda Pharmaceutical Company Limited (Takeda) announced that on July 7, 2009 Wyeth had received approval from the Japanese Ministry of Health, Labour and Welfare to add the indication of treating polyarticular Juvenile Idiopathic Arthritis (JIA) to “ENBREL 25mg for S.C. Injection,” (etanercept) which Wyeth and Takeda co-promote.
(AP) — Shares of Amgen Inc. surged more than 13 percent in Tuesday after-hours trading, after the Thousand Oaks drugmaker said a late-stage clinical trial showed its experimental osteoporosis drug denosumab outperformed a rival product at preventing bone injuries in breast cancer patients. Amgen said patients treated with denosumab were free of skeletal injury — including fracture, bone ...
SAN DIEGO, INDIANAPOLIS and CAMBRIDGE, Mass., July 7 /PRNewswire-FirstCall/ -- Amylin Pharmaceuticals, Inc., (Nasdaq: AMLN), Eli Lilly and Company (NYSE: LLY) and Alkermes, Inc.
(AP:THOUSAND OAKS, Calif.) Shares of Amgen Inc. surged more than 13 percent in Tuesday after-hours trading, after the drugmaker said a late-stage clinical trial showed its experimental osteoporosis drug denosumab outperformed a rival product at preventing bone injuries in breast cancer patients.
THIS DIARY IS FILED AS THE FOOD AND DRUG ADMINISTRATION UPDATES ITS SCHEDULE. ALL TIMES EDT/GMT. For more information on the FDA's Advisory Committee meetings, see: http://www.fda.gov/AdvisoryCommittees/Calendar/default.htm
SAN DIEGO, INDIANAPOLIS & CAMBRIDGE, Mass.----Amylin Pharmaceuticals, Inc., , Eli Lilly and Company and Alkermes, Inc. today announced that the New Drug Application for exenatide once weekly has been accepted for review by the U.S.
FREMONT, Calif.----Zosano Pharma, Inc., a privately held pharmaceutical company developing products based on its novel transdermal delivery technology, today announced that the company has closed a new round of financing in the amount of $30 million.
Schering-Plough Corp., announced results from the phase III Engage clinical trial demonstrating that a single injection of corifollitropin alfa, first in the class of sustained follicle stimulants, achieved similar efficacy to recombinant follicle stimulating hormone (rFSH) given once daily for seven days.
Convergent technologies are making new frontiers in medicine possible. Convergent technologies just may be the key to the future of medicine. Advances in nanotechnology, coatings, and molecular diagnostics have blurred the lines of devices and pharmaceuticals.
Related News Resources:
> HGH News
|
Breaking News
and Top Stories |
Business
Earnings, Economy, Personal Finance, and Stock Markets |
Entertainment
Books, Celebrity, Fashion, Movies, Music, Television, and Theatre |
Health
Aging, Diseases, Medical Conditions, Medications, Sexual Health, and Weight Loss |
Politics
Congress, Supreme Court, and White House |
|
Science
Animals, Astronomy, Biotechnology, Space, and Weather |
Sports
Baseball, Basketball, Boxing, Football, Golf, Hockey, Motor Sports, Soccer, and Tennis |
Technology
Communications, Hardware, Internet, Personal Technology, and Software |
United States
and Crimes and Trials |
World
Africa, Antartica, Asia, Australia, Canada, Europe, Latin America, and Middle East |